I think Invion has done all it can with this drug by demonstrating a dose/response relationship and presenting safety at much higher doses than those trialled earlier. The market is not excited and I think Invion need to organise a partner for some dollars to progress their inhaled business. Bring on the nadolol studies and quickly please because I prefer to see green on my screen not red.
Ann: INV103 ala-Cpn10 clinical trial in lupus complete, page-12
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.81M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 5199274 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 5634077 | 10 |
View Market Depth
| Last trade - 10.04am 07/08/2024 (20 minute delay) ? |
| IVX (ASX) Chart |
Day chart unavailable